Banque Cantonale Vaudoise Makes New $3.03 Million Investment in Edwards Lifesciences Corporation (NYSE:EW)

Key Points

• Banque Cantonale Vaudoise has initiated a new investment in Edwards Lifesciences, acquiring 41,767 shares valued at approximately $3.03 million during the first quarter.
• Several institutional investors have recently adjusted their holdings, indicating significant interest in the company, with institutional ownership now at 79.46%.
• Edwards Lifesciences reported an EPS of $0.67 for the last quarter, surpassing analysts' estimates, and showed an 11.9% year-over-year revenue growth with $1.53 billion in revenue.

Banque Cantonale Vaudoise acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund acquired 41,767 shares of the medical research company's stock, valued at approximately $3,028,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. Global X Japan Co. Ltd. lifted its holdings in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. Tradewinds Capital Management LLC lifted its stake in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares during the period. Rossby Financial LCC bought a new position in Edwards Lifesciences during the 1st quarter valued at approximately $29,000. Finally, ORG Wealth Partners LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $38,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.01 during mid-day trading on Friday, reaching $79.30. The company had a trading volume of 3,152,852 shares, compared to its average volume of 4,898,219. Edwards Lifesciences Corporation has a 52-week low of $59.41 and a 52-week high of $83.00. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $46.52 billion, a P/E ratio of 11.41, a PEG ratio of 3.84 and a beta of 1.08. The stock has a 50 day moving average of $76.82 and a two-hundred day moving average of $73.74.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.25% and a net margin of 72.96%. Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.70 earnings per share. On average, analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on EW. Barclays raised their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Morgan Stanley lifted their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a report on Friday, July 25th. Finally, Wall Street Zen raised Edwards Lifesciences from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, thirteen have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average target price of $85.71.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the transaction, the chief financial officer directly owned 41,098 shares in the company, valued at $3,057,691.20. This trade represents a 21.49% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,962 shares of company stock valued at $2,641,387. Insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.